Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Expedia Group Inc (EXPE) Price & Performance

AbCellera Biologics IncTrade
Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Expedia Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.36 (market cap $2.85B), while Expedia Group Inc trades at $315 (market cap $37.69B). The key difference: Expedia Group Inc is far larger — about 13.2× AbCellera Biologics Inc's market cap, and Expedia Group Inc pays a 0.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLEXPE
Market Cap
$2.85B$37.69B
Sector
HealthConsumer Cyclical
52-Week High
$9.34$319.66
52-Week Low
$2.78$188.51
Enterprise Value
$2.45B$36.25B
Dividend Yield
0.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Expedia Group Inc

Expedia Group (EXPE) trades at $310.68, up 1.34% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. The company reported Q2 2026 EPS of $5.76, exceeding expectations, driven by 14% revenue growth and robust B2B performance. Valuation metrics include a P/E of 19.54 and P/S of 2.51, with net income margin improving to 12.97% in 2025. Recent news highlights AI integration and raised full-year guidance, reflecting operational strength.

The outlook for EXPE is positive, with earnings momentum and strategic expansions offering upside potential, though high debt levels and travel industry volatility pose risks. Analysts project a consensus price target of $322.95, with 47% buy ratings, indicating cautious optimism. Investors should weigh solid fundamentals against macroeconomic sensitivities affecting travel demand.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE